晚期胰腺癌短期或中期高死亡风险患者全身肿瘤治疗的疗效:系统综述再综述
该再综述评估晚期胰腺癌高短期或中期死亡风险患者接受全身肿瘤治疗对比支持治疗的证据。纳入三项系统综述,方法学质量均为极低。12个月总生存期在化疗、放疗后化疗及免疫治疗中改善,但证据确定性极低;化疗对生活质量影响很不确定,毒性略增,功能状态几乎无差异。
要点
- 纳入的三项系统综述方法学质量均为极低。
- 12个月总生存期改善见于化疗、放疗后化疗及免疫治疗,但证据确定性极低。
- 化疗对生活质量影响很不确定,毒性略增,功能状态几乎无差异。
核心结论
- 已识别的证据对晚期胰腺癌高短期或中期死亡风险患者的全身肿瘤治疗在总生存期和生活质量方面的获益非常不确定,应仅考虑用于特定患者。
研究设计与样本
- 系统综述再综述,检索MEDLINE、Embase、Cochrane Library、Epistemonikos和PROSPERO。
- 由两名作者独立评估 eligibility,数据提取和方法学质量评估由一名作者完成并由另一名交叉核对。
- 评估了原始研究重叠,进行了de novo meta分析,并评估了证据确定性。
主要发现
- 共识别三项系统综述,评估晚期胰腺癌患者全身肿瘤治疗对比支持治疗。
- 12个月总生存期在化疗、放疗后化疗和免疫治疗中改善,但支持这些发现的证据确定性极低。
- 化疗对生活质量影响的证据非常不确定,提示毒性略有增加,功能状态几乎无差异。
- 免疫治疗对毒性影响的证据非常不确定。
临床怎么用
- 全身肿瘤治疗应仅考虑用于经过选择的晚期胰腺癌高短期或中期死亡风险患者。
局限性
- 纳入的系统综述方法学质量均为极低。
- 支持总生存期和生活质量获益的证据确定性极低或非常不确定。
- 需要进一步开展包含全面患者中心结局评估的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with advanced pancreatic cancer (PC) have a high risk of dying in the short or medium-term. This overview aimed to assess the evidence regarding systemic oncological treatments (SOT) versus supportive care for advanced PC. METHODS: We searched for systematic reviews (SRs) in MEDLINE, Embase, The Cochrane Library, Epistemonikos, and PROSPERO. Two authors assessed eligibility independently. Data extraction and methodological quality assessment were conducted by one author and cross-checked by another one. We evaluated the overlap of primary studies, performed a de novo meta-analysis, and assessed the certainty of evidence. Primary outcomes were overall survival (OS), quality of life (QoL), functional status (FS), and toxicity. RESULTS: We identified three SRs that assessed SOT versus supportive care in patients with advanced PC. All SRs had critically low methodological quality. At 12 months, OS improved with chemotherapy, radiotherapy followed by chemotherapy, and immunotherapy, but the certainty of the evidence supporting these findings is very low. The evidence on chemotherapy is very uncertain about its effects on QoL; it suggests a slight increase in toxicity and little to no difference in FS. The evidence on immunotherapy is very uncertain about its effects in toxicity. CONCLUSIONS: The identified evidence is very uncertain about the benefits of oncological treatments on OS and QoL in patients with advanced PC with a high risk of dying in the short or medium-term, so its use should be proposed only to selected patients. Further studies that include a thorough assessment of patient-centred outcomes are needed.
引用
- Salazar J, Pérez-Bracchiglione J, Salas-Gama K, et al. Efficacy of systemic oncological treatments in patients with advanced pancreatic cancer at high risk of dying in the short or medium-term: overview of systematic reviews. Eur J Cancer. 2021. PMID: 34252759. doi:10.1016/j.ejca.2021.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。